- XOMA Declares Quarterly Preferred Stock Dividends
- XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher
- XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
- XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
- XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
- XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
- XOMA Corporation Announces Closing of Tender Offer
- XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
- XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
- XOMA to Present at Upcoming Investor Conferences in March
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 24.20 |
---|---|
High | 24.20 |
Low | 24.00 |
Bid | 24.00 |
Offer | 24.80 |
Previous close | 23.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 11.64m |
Free float | 11.58m |
P/E (TTM) | -- |
Market cap | 301.44m USD |
EPS (TTM) | -3.92 USD |
Annual div (ADY) | 2.00 EUR |
---|---|
Annual div yield (ADY) | 8.43% |
Div ex-date | Jul 03 2024 |
Div pay-date | Jul 15 2024 |
Data delayed at least 15 minutes, as of Jul 04 2024 08:59 BST.
More ▼